drugset / Trial / NCT00489476

Staccato Loxapine in Migraine (in Clinic)

NCT00489476

Phase 2 Completed 168 enrolled Alexza Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this trial is to assess the efficacy and safety of Staccato Loxapine in patients with migraine headache with or without aura in a clinical setting.

Timeline

Start
2007-06
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject loxapine Small molecule 1.25 mg Inhaled
Subject loxapine Small molecule 2.5 mg Inhaled
Subject loxapine Small molecule 5 mg Inhaled

Indications